<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511433306</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511433306</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Teunissen</surname><given-names>CE</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511433306">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sombekke</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511433306">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van Winsen</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511433306">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Killestein</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511433306">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511433306">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511433306">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dijkstra</surname><given-names>CD</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511433306">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Blankenstein</surname><given-names>MA</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511433306">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pratico</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff4-1352458511433306">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511433306"><label>1</label>Department of Clinical Chemistry, VU University Medical Center, The Netherlands</aff>
<aff id="aff2-1352458511433306"><label>2</label>Department of Neurology, VU University Medical Center, The Netherlands</aff>
<aff id="aff3-1352458511433306"><label>3</label>Department of Radiology, VU University Medical Center, The Netherlands</aff>
<aff id="aff4-1352458511433306"><label>4</label>Department of Pharmacology, Temple University, USA</aff>
<author-notes>
<corresp id="corresp1-1352458511433306">CE Teunissen, Department of Clinical Chemistry, VU University Medical Center, FdG, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Email: <email>c.teunissen@vumc.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>8</issue>
<fpage>1092</fpage>
<lpage>1098</lpage>
<history>
<date date-type="received">
<day>21</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>11</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>11</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458511433306">
<title>Background:</title>
<p>Oxidative stress plays an important role in multiple sclerosis (MS). Isoprostanes are biomarkers for oxidative stress and have been related to neurological disease progression.</p>
</sec>
<sec id="section2-1352458511433306">
<title>Objective:</title>
<p>To study whether plasma isoprostane levels were related to disease progression in MS.</p>
</sec>
<sec id="section3-1352458511433306">
<title>Methods:</title>
<p>Plasma levels of 8,12-iso-iPF2alpha-VI were determined in 17 patients with clinically isolated syndrome (CIS), 41 relapsing–remitting MS (RRMS) patients and 5 primary progressive MS (PPMS) patients and related to MRI and clinical disease parameters.</p>
</sec>
<sec id="section4-1352458511433306">
<title>Results:</title>
<p>Isoprostane levels were similar in CIS (60.9, interquartile range (IQR): 47.7–77.7 pg/ml) and RRMS patients (65.3, IQR: 51.9–82.8 pg/ml). The plasma levels were lower in PPMS patients (42.5, IQR: 37.1–49.9) pg/ml, <italic>p</italic>&lt;0.05) compared to CIS and RRMS patients in this cohort, which was not confirmed in a second cohort. Baseline isoprostane levels were not related to clinical progression defined by conversion form CIS to RRMS or change in Expanded Disability Status Scale (EDSS) or MS Functional Composite (MSFC) scores during six years of follow-up (CIS + RRMS), nor to change in volume of gadolinium enhancing lesions, T2 lesion load or T1 hypointense lesion load during 2.8 years of follow-up (CIS + RRMS).</p>
</sec>
<sec id="section5-1352458511433306">
<title>Conclusion:</title>
<p>These results do not support a strong role of 8,12-iso-iPF2alpha-VI in the prediction of disease progression in MS.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Multiple sclerosis</kwd>
<kwd>clinically isolated syndrome</kwd>
<kwd>biomarkers</kwd>
<kwd>isoprostanes</kwd>
<kwd>oxidative stress</kwd>
<kwd>plasma</kwd>
<kwd>progression</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458511433306" sec-type="intro">
<title>Introduction</title>
<p>Oxidative stress is an important mechanism during multiple sclerosis (MS) pathology. Reactive oxygen species (ROS) are involved in blood brain barrier damage and cellular infiltration into the brain parenchyma. The production of high levels of toxic ROS by activated macrophages in MS lesions probably plays a major role in myelin and axonal damage.<sup><xref ref-type="bibr" rid="bibr1-1352458511433306">1</xref><xref ref-type="bibr" rid="bibr2-1352458511433306"/>–<xref ref-type="bibr" rid="bibr3-1352458511433306">3</xref></sup> Furthermore, ROS are involved in mitochondrial dysfunction in MS.<sup><xref ref-type="bibr" rid="bibr4-1352458511433306">4</xref></sup> Oxidative stress may also play a crucial role in early stages of the pathogenesis, as nitration of axonal mitochondrial proteins due to peroxynitrite formation has been observed early in the disease course of experimental autoimmune encephalitis (EAE), before the emergence of clinical signs and infiltration of inflammatory cells.<sup><xref ref-type="bibr" rid="bibr5-1352458511433306">5</xref></sup></p>
<p>The occurrence of oxidative stress in MS pathology is also indicated by biomarker studies in blood serum or plasma. For example, serum antioxidant levels were decreased and lipid peroxidation markers, such as thiobarbituric acid reacting substances (TBARS), were increased in CIS or MS patients.<sup><xref ref-type="bibr" rid="bibr6-1352458511433306">6</xref><xref ref-type="bibr" rid="bibr7-1352458511433306"/>–<xref ref-type="bibr" rid="bibr8-1352458511433306">8</xref></sup> Plasma levels of lipid peroxidation products, such as cholesteryl ester hydroperoxides or fluorescent lipid peroxidation products, were elevated in MS.<sup><xref ref-type="bibr" rid="bibr9-1352458511433306">9</xref>,<xref ref-type="bibr" rid="bibr10-1352458511433306">10</xref></sup> In view of the crucial role of oxidative stress in several aspects of MS pathology, especially neuronal functioning, it may be expected that biomarkers for oxidative stress are related to clinical disease progression. No serum or plasma oxidative stress biomarkers that predict disease progression in MS are available yet.</p>
<p>Candidate markers for oxidative stress in patients with neurodegenerative diseases are F2-isoprostanes. Isoprostanes are isomers of prostaglandin that are formed by the non-enyzmatic oxidation of fatty acids. CSF levels of the isoprostane 8-epi-prostaglandin-F2alpha were three times higher in MS patients (<italic>n</italic>=26) compared to neurological control patients (<italic>n</italic>=8)<sup><xref ref-type="bibr" rid="bibr11-1352458511433306">11</xref></sup> and a correlation with Expanded Disability Status Scale (EDSS) scores has been observed (<italic>r</italic>=0.48).<sup><xref ref-type="bibr" rid="bibr12-1352458511433306">12</xref></sup> Another study showed increased levels of isoprostanes in the urine of secondary progressive MS (SPMS) patients compared to controls.<sup><xref ref-type="bibr" rid="bibr13-1352458511433306">13</xref></sup> A recent study including a larger patient group, however, did not show elevated CSF levels of another more CNS specific F2-isoprostane, 8,12-iso-iPF2alpha-VI, in relapsing–remitting MS (RRMS) patients and SPMS patients compared to controls, though levels were increased in healthy siblings.<sup><xref ref-type="bibr" rid="bibr14-1352458511433306">14</xref></sup> Elevated plasma and CSF levels of this isoprostane have been observed in patients with mild cognitive impairment or Alzheimer’s disease (AD),<sup><xref ref-type="bibr" rid="bibr15-1352458511433306">15</xref>,<xref ref-type="bibr" rid="bibr16-1352458511433306">16</xref></sup> and have been related to conversion from mild cognitive impairment to AD.<sup><xref ref-type="bibr" rid="bibr17-1352458511433306">17</xref></sup> So far, it is not known if plasma isoprostane levels could be used as a biomarker for ongoing oxidative stress in MS pathology. Plasma could be a good source for biomarkers and is more convenient to collect than CSF, although it is separated from the pathological tissue by the blood-brain barrier.</p>
<p>The prodrome in 85% of cases of MS is a clinically isolated syndrome (CIS), which is defined by an acute or subacute episode of neurological disturbance due to a single white matter lesion.<sup><xref ref-type="bibr" rid="bibr18-1352458511433306">18</xref></sup> About 30–70% of the CIS cases convert into full-blown MS.<sup><xref ref-type="bibr" rid="bibr18-1352458511433306">18</xref></sup> Since CIS and definite MS are highly likely characterized by similar mechanisms, though at a different intensity, we expect that this is reflected in a different level of oxidative stress biomarkers in RRMS patients compared to CIS patients and a higher levels in patients shortly before conversion. Furthermore, we expect higher levels in RRMS patients compared to primary progressive MS (PPMS) patients due to the lower inflammatory activity in PPMS patients.<sup><xref ref-type="bibr" rid="bibr19-1352458511433306">19</xref></sup></p>
<p>In this study, we set out to investigate the levels of 8,12-iso-iPF2alpha-VI in the plasma of CIS and MS patients and their relation with disease prognosis in MS. We compared plasma levels between CIS patients, clinically definite RRMS and PPMS patients and correlated the levels with changes in clinical and MRI parameters over two years of follow-up. To establish if plasma levels were correlated to CSF levels, the body fluid studied in previously published studies, we also examined F2-isoprostane levels in a second cohort using paired CSF/plasma samples.</p>
</sec>
<sec id="section7-1352458511433306" sec-type="methods">
<title>Methods</title>
<sec id="section8-1352458511433306">
<title>Patients</title>
<p>All participants gave written informed consent and the local ethics committee approved the study.</p>
<sec id="section9-1352458511433306">
<title>Longitudinal cohort</title>
<p>A random sample of 63 patients was selected from an ongoing prospective cohort study in CIS and early MS (diagnosis&lt;6 months before inclusion). MS patients were diagnosed according to the Poser criteria<sup><xref ref-type="bibr" rid="bibr20-1352458511433306">20</xref></sup> and CIS patients were evaluated according to the Barkhof/Tintoré criteria.<sup><xref ref-type="bibr" rid="bibr21-1352458511433306">21</xref></sup> Patient characteristics are presented in <xref ref-type="table" rid="table1-1352458511433306">Table 1</xref>. At baseline, a plasma sample was drawn and patients underwent an MRI and clinical testing, including the MS Functional Composite (MSFC) and EDSS.<sup><xref ref-type="bibr" rid="bibr22-1352458511433306">22</xref>,<xref ref-type="bibr" rid="bibr23-1352458511433306">23</xref></sup></p>
<table-wrap id="table1-1352458511433306" position="float">
<label>Table 1.</label>
<caption>
<p>Patient characteristics in the longitudinal plasma study.</p>
</caption>
<graphic alternate-form-of="table1-1352458511433306" xlink:href="10.1177_1352458511433306-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">MS subtype</th>
<th align="left">CIS</th>
<th align="left">RRMS</th>
<th align="left">PPMS</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>n</italic></td>
<td>17</td>
<td>41</td>
<td>5</td>
</tr>
<tr>
<td>Female /male ratio (%)</td>
<td>9/9 (50)</td>
<td>22/19 (54)</td>
<td>2/3 (40)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>34.8 (8.1)</td>
<td>33.7 (8.3)</td>
<td>45.7 (8.2)<sup><xref ref-type="table-fn" rid="table-fn3-1352458511433306">a</xref></sup></td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>1.6 (2)</td>
<td>2.5 (2)</td>
<td>4.8 (3.1)</td>
</tr>
<tr>
<td>Number of patients in relapses (%)</td>
<td>6/14 (43)</td>
<td>14/36 (39)</td>
<td>0/4 (0)</td>
</tr>
<tr>
<td>Isoprostanes (pg/ml)</td>
<td>60.9 (47.7–77.7)</td>
<td>65.3 (51.9–82.8)</td>
<td>42.5 (37.1–49.9)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511433306">
<p>CIS: clinically isolated syndrome; MS: multiple sclerosis; PPMS: primary progressive MS; RRMS: relapsing–remitting MS.</p>
</fn>
<fn id="table-fn2-1352458511433306">
<p>Data are presented as means (SD) except for Isoprostanes, which are presented as medians and interquartile range.</p>
</fn>
<fn id="table-fn3-1352458511433306">
<label>a</label>
<p>Significantly different from CIS and RRMS patients (analysis of variance (ANOVA), posthoc analysis (Bonferroni) <italic>p</italic>&lt;0.04).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Butylated hydroxytoluene was added to plasma samples immediately after centrifugation to avoid autooxidation. Samples were stored maximal seven months at -20°C until analysis.</p>
<p>MRI-acquisition was performed at 1.0 Tesla (Siemens, Erlangen, Germany) and consisted of axial pre- and post-contrast T1-weighted (repetition time (TR)=700 ms, echo time (TE)=15 ms, 5.5 mm slice thickness) images and T2-weighted (TR=2700 ms, TE=90 ms, 5.5 mm slice thickness) images. T1 hypointense lesion load (T1LL), T2 lesion load (T2LL) and volume of gadolinium enhancing lesions (GADLL) were quantified using home-developed semi-automated seed growing software based on a local thresholding technique.</p>
<p>For 18 patients, no baseline scan obtained within three months was available, and for one patient the scan was of insufficient quality to be analysed.</p>
<p>Thirty-seven patients were re-evaluated after two years and a second set of clinical scores and MRI parameters was obtained (<italic>n</italic>=37 for MRI, see <xref ref-type="table" rid="table2-1352458511433306">Table 2</xref>).</p>
<table-wrap id="table2-1352458511433306" position="float">
<label>Table 2.</label>
<caption>
<p>Clinical data at baseline and follow-up.</p>
</caption>
<graphic alternate-form-of="table2-1352458511433306" xlink:href="10.1177_1352458511433306-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">MS subtype</th>
<th/>
<th align="left">CIS</th>
<th align="left">RRMS</th>
<th align="left">PPMS</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>n</italic></td>
<td>Baseline</td>
<td>15</td>
<td>36</td>
<td>4</td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>10</td>
<td>39</td>
<td>4</td>
</tr>
<tr>
<td>Interval between baseline and follow-up</td>
<td/>
<td>5.1 (3.3–6.3)</td>
<td>6.0 (5.6–6.3)</td>
<td>4.1 (3.3–5.9)</td>
</tr>
<tr>
<td>EDSS</td>
<td>Baseline</td>
<td>2.3 (1.5, 3.0)</td>
<td>2.0 (1.1, 2.9)</td>
<td>4.3 (2.9, 5.3)<sup><xref ref-type="table-fn" rid="table-fn6-1352458511433306">a</xref></sup></td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>2 (1–3.1)</td>
<td>2 (1.5–3.5)</td>
<td>6 (4.8–7.6)</td>
</tr>
<tr>
<td>9HPT_D</td>
<td>Baseline</td>
<td>16.9 (14.9–18.3)</td>
<td>17.8 (16.2–20.3)</td>
<td>22.6 (17.4–23.3)</td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>16.8 (16–18.6)</td>
<td>19.2 (17.6–22.4)</td>
<td>34.9 (20.3–236.3)</td>
</tr>
<tr>
<td>9HPT_ND</td>
<td>Baseline</td>
<td>19.2 (17.5–20.3)</td>
<td>18.8 (17.6–20.4)</td>
<td>22.5 (18.2–26.1)</td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>18.9 (17.7–20.7)</td>
<td>19.5 (17.6–23.4)</td>
<td>24.9 (20.7–231.4)</td>
</tr>
<tr>
<td>PASAT</td>
<td>Baseline</td>
<td>56 (50–59)</td>
<td>53 (45.3–58)</td>
<td>53 (44–58.3)</td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>53.5 (43.8–58.5)</td>
<td>56 (50–59)</td>
<td>55 (33.8–59)</td>
</tr>
<tr>
<td>Timed Walk Test</td>
<td>Baseline</td>
<td>3.7 (3.6–4.8)</td>
<td>3.8 (3.4–4.6)</td>
<td>4.4 (3.8–6.5)</td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>3.8 (3.4–4.4)</td>
<td>3.7 (3.6–5.2)</td>
<td>93.8 (6.4–180)</td>
</tr>
<tr>
<td>Use of disease modifying therapy during follow-up period</td>
<td/>
<td>3</td>
<td>20</td>
<td>2 (IVIG, mitoxantrone)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1352458511433306">
<p>CIS: clinically isolated syndrome; EDSS: Expanded Disability Status Scale; 9HPT_D: 9-Hole Peg Test, dexterior hand; 9HPT_ND: 9-Hole Peg Test, non-dexterior hand; MS: multiple sclerosis; ns: not significant; PASAT: Paced Auditory Serial Addition Test; PPMS: primary progressive MS; RRMS: relapsing–remitting MS.</p>
</fn>
<fn id="table-fn5-1352458511433306">
<p>Data shown are median (interquartile range) unless otherwise indicated.</p>
</fn>
<fn id="table-fn6-1352458511433306">
<label>a</label>
<p>Significantly different from CIS and RR patients (analysis of variance (ANOVA), posthoc analysis (Bonferroni) <italic>p</italic>&lt;0.034).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The EDSS was performed by trained medical doctors, as were the individual components of the MSFC (25-foot Timed Walk Test (TWT), 9-Hole Peg Test (9HPT) and the three second Paced Auditory Serial Addition Test (PASAT3)). Fifty-five patients underwent EDSS assessment and examination of the components of the MSFC at baseline. MRI examination was performed on the same day as the blood withdrawal. EDSS and components of the MSFC were also determined at follow-up of minimal one year (median 6 years, interquartile range (IQR): 5.5–6.3) after blood withdrawal in 53 patients.</p>
</sec>
<sec id="section10-1352458511433306">
<title>CSF-plasma cohort</title>
<p>Paired plasma and CSF samples were collected from a group of 29 MS patients diagnosed according to the Poser criteria, as part of an ongoing research project on CSF in MS and in agreement with the BIoMS-eu guidelines.<sup><xref ref-type="bibr" rid="bibr24-1352458511433306">24</xref></sup> Patients were recruited either in response to an appeal in the periodical of the Dutch MS society, or from patients visiting or admitted at our clinic, and were requested to voluntarily undergo a lumbar puncture, MRI, and clinical testing. Some patients underwent a lumbar puncture for diagnostic purposes. In that case, additional CSF was collected for research purposes with the patients’ consent. These patients were classified as having a RRMS (<italic>n</italic>=10), SPMS (<italic>n</italic>=9) or PPMS (<italic>n</italic>=10) disease course.<sup><xref ref-type="bibr" rid="bibr25-1352458511433306">25</xref></sup> Prior to lumbar puncture patients underwent clinical (EDSS) and examination as described above. Patients underwent MRI examination on the same day as the lumbar puncture (<italic>n</italic>=17), or in the range from one week before until two weeks after the puncture, with the same protocol as for the longitudinal cohort.</p>
<p>Additionally, CSF was collected from 8 patients with other neurological diseases and symptoms (OND) that underwent a diagnostic lumbar puncture. These patients had the following complaints/syndromes: no neurological disease (<italic>n</italic>=4), vascular disease (<italic>n</italic>=2), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (<italic>n</italic>=1), and polyneuropathy (<italic>n</italic>=1). These patients had no specific abnormalities at MRI scan and CSF examination. Butylated hydroxytoluene was added to these CSF and plasma samples immediately after thawing to prevent auto-oxidation.</p>
</sec>
</sec>
<sec id="section11-1352458511433306">
<title>Analysis of 8,12-iso-iPF2alpha-VI</title>
<p>8,12-iso-iPF2alpha-VI in body fluids were measured according to previously published methods.<sup><xref ref-type="bibr" rid="bibr16-1352458511433306">16</xref></sup> Samples were spiked with a fixed amount of internal standard (d4-iPF2alpha-VI) and extracted on a C18 cartridge column. The eluate was purified by thin-layer chromatography/mass spectrometry. The detection limit for tvhe assay was 1 pg/mL and the coefficient of variation ranged from 4–8% (intra-assay) and 5–8% (inter-assay).</p>
</sec>
<sec id="section12-1352458511433306">
<title>Statistical analysis</title>
<p>Data are presented as medians with IQR unless otherwise specified. Normality of the distribution was analysed with a Shapiro-Wilk test. Since normality was rejected, nonparametric statistics were used. Multiple group comparisons were performed using the Kruskal-Wallis test. When the result was significant, a pairwise comparison was done using the Mann-Whitney U test. Correlation analyses were performed using Spearman correlations. A <italic>p</italic> value&lt;0.05 was considered as significant.</p>
</sec>
</sec>
<sec id="section13-1352458511433306" sec-type="results">
<title>Results</title>
<sec id="section14-1352458511433306">
<title>Longitudinal cohort</title>
<sec id="section15-1352458511433306">
<title>Population characteristics</title>
<p>The results in <xref ref-type="table" rid="table1-1352458511433306">Table 1</xref> show that baseline age was higher in the PPMS patients compared to the CIS and RRMS patients (<italic>p</italic>&lt;0.05). The disease duration and female/male ratio were not different between the clinical subgroups.</p>
</sec>
<sec id="section16-1352458511433306">
<title>Plasma isoprostane levels in different clinical groups</title>
<p>The plasma concentrations of 8,12-iso-iPF2alpha-VI are represented in <xref ref-type="fig" rid="fig1-1352458511433306">Figure 1</xref> and <xref ref-type="table" rid="table1-1352458511433306">Table 1</xref>. Overall comparison of isoprostane levels at baseline showed a difference between the groups (Kruskal-Wallis test: Chi=8.6, <italic>p</italic>=0.013). Plasma levels of 8,12-iso-iPF2alpha-VI were increased in CIS and RRMS patients compared to PPMS patients (Pair wise comparison: <italic>Z</italic>= −2.2, <italic>p</italic>=0.031 for CIS vs PPMS and <italic>Z</italic>=-2.8, <italic>p</italic>=0.002 for RRMS vs PPMS).</p>
<fig id="fig1-1352458511433306" position="float">
<label>Figure 1.</label>
<caption>
<p>Levels of 8,12-iso-iPF2alpha-VI in the plasma of patients with clinically isolated syndrome (CIS) or multiple sclerosis (MS).</p>
<p>PPMS: primary progressive MS; RRMS: relapsing–remitting MS.</p>
<p>Data are medians and interquartile ranges.</p>
<p>*<italic>p</italic>&lt;0.05.</p>
</caption>
<graphic xlink:href="10.1177_1352458511433306-fig1.tif"/>
</fig>
<p>Pair-wise comparison of 8,12-iso-iPF2alpha-VI levels in samples obtained after three months (<italic>n</italic>=11) showed an increase in the level after follow-up (<italic>p</italic>&lt;0.05).</p>
<p>No significant correlation was present between plasma 8,12-iso-iPF2alpha-VI levels and age or disease duration at baseline. There was a tendency for 8,12-iso-iPF2alpha-VI levels being higher in the patients that also underwent intravenous treatment with methylprednisolone (treated: 78.2 (IQR: 57.8–89.7, <italic>n</italic>=21; never treated: 62.5 (IQR: 48.9–77.8), <italic>n</italic>=33, <italic>p</italic>=0.069), but the levels independent of use of disease modifying therapies during the follow-up period. No correlation between 8,12-iso-iPF2alpha-VI levels and time between treatment and blood withdrawal was present (<italic>r</italic>=-0.231, <italic>p</italic>=0.3).</p>
</sec>
<sec id="section17-1352458511433306">
<title>Relation of 8,12-iso-iPF2alpha-VI levels in plasma with clinical disease progression</title>
<p>The mean EDSS score and the separate components of the MSFC at baseline were comparable between the CIS and RRMS patients. The EDSS scores were worse in the PPMS patients compared to the CIS and RRMS patients.</p>
<p>No correlation was observed between baseline plasma 8,12-iso-iPF2alpha-VI levels and EDSS score and components of the MSFC score at baseline or after a median long-term follow-up of 6 years, nor with the yearly change in these variables (data not shown). These data were the same after correction for use of disease modifying therapies during the follow-up period or age.</p>
<p>No differences in plasma 8,12-iso-iPF2alpha-VI levels were observed for patients that converted into MS (<italic>n</italic>=5) compared to patients that did not convert (<italic>n</italic>=12) (<italic>Z</italic>=-1.5, <italic>p</italic>=0.15). Twenty patients were in a relapse, but levels of plasma 8,12-iso-iPF2alpha-VI were not higher compared to patients in remissions (data not shown). The mean time until the next relapse was 12.6 (range 0–58) months for four CIS patients (for one this was unknown) and 12.2 (range 1–46) months for 24 RRMS patients. There was no correlation between plasma 8,12-iso-iPF2alpha-VI levels and time to next relapse in the MS group as a whole or in the different clinical subtypes. Also, 14 CIS patients had a relapse 10 (range 0–33) months before blood withdrawal, 36 RRMS patients had a relapse 10 (range 0–32) months. No correlation was observed between this time-range and isoprostane concentrations (Spearman <italic>r</italic>=-0.119, <italic>p</italic>=0.39).</p>
</sec>
<sec id="section18-1352458511433306">
<title>Relation with radiological parameters of disease progression</title>
<p>The MRI characteristics in each of the clinical groups are presented in <xref ref-type="table" rid="table3-1352458511433306">Table 3</xref>. The volume of hypointense T1 lesions was higher in RRMS patients compared to CIS patients at follow-up, and a tendency for an increase in T2LL in RRMS was observed. The annual change in T2LL was higher in the RRMS patients compared to the CIS patients (<italic>p</italic>=0.027). The number of scans in the PPMS group was too low (<italic>n</italic>=2) for reliable comparison with the other groups.</p>
<table-wrap id="table3-1352458511433306" position="float">
<label>Table 3.</label>
<caption>
<p>Radiological characteristics at baseline and follow-up.</p>
</caption>
<graphic alternate-form-of="table3-1352458511433306" xlink:href="10.1177_1352458511433306-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">MS subtype</th>
<th/>
<th align="left">CIS</th>
<th align="left">RRMS</th>
<th align="left">PPMS</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>n</italic></td>
<td>Baseline</td>
<td>12</td>
<td>29</td>
<td>2</td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>8</td>
<td>27</td>
<td>2</td>
</tr>
<tr>
<td>Interval (years)</td>
<td/>
<td>2 (2–2.3)</td>
<td>2.8 (2–3.3) (ns from CIS)</td>
<td/>
</tr>
<tr>
<td>T1LL</td>
<td>Baseline</td>
<td>37 (0–157)</td>
<td>142 (0–473)</td>
<td>No values due to low <italic>n</italic></td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>0 (0–28.8)</td>
<td>218 (0–643)<sup><xref ref-type="table-fn" rid="table-fn9-1352458511433306">a</xref></sup></td>
<td>No values due to low <italic>n</italic></td>
</tr>
<tr>
<td>T2LL</td>
<td>Baseline</td>
<td>1122 (343–4024)</td>
<td>1877 (570–4938)<sup><xref ref-type="table-fn" rid="table-fn10-1352458511433306">b</xref></sup></td>
<td>No values due to low <italic>n</italic></td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>942 (186–2782)</td>
<td>2028 (702–7422)</td>
<td>No values due to low <italic>n</italic></td>
</tr>
<tr>
<td>GADLL</td>
<td>Baseline</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>No values due to low <italic>n</italic></td>
</tr>
<tr>
<td/>
<td>Follow-up</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>No values due to low <italic>n</italic></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1352458511433306">
<p>CIS: clinically isolated syndrome; GADLL: gadolinium enhancing lesions; MS: multiple sclerosis; PPMS: primary progressive MS; RRMS: relapsing– remitting MS; ns: not significant; T1LL: T1 hypointense lesion load; T2LL: T2 lesion load.</p>
</fn>
<fn id="table-fn8-1352458511433306">
<p>Data shown are median (interquartile range)).</p>
</fn>
<fn id="table-fn9-1352458511433306">
<label>a</label>
<p>Significant difference between RRMS and CIS, <italic>p</italic>&lt;0.019.</p>
</fn>
<fn id="table-fn10-1352458511433306">
<label>b</label>
<p>Tendency for difference between RRMS and CIS, <italic>p</italic>&lt;0.056.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>No correlation between plasma isoprostane-levels and any of the cross-sectional MRI parameters or change in MRI parameters over two years was observed in the total group of MS patients or within the clinical subgroups.</p>
</sec>
</sec>
<sec id="section19-1352458511433306">
<title>CSF-plasma cohort</title>
<sec id="section20-1352458511433306">
<title>Correlation between plasma and CSF</title>
<p>We analyzed the paired CSF and plasma levels of 8,12-iso-iPF2alpha-VI in another, independent cohort. CSF and plasma levels were intermediately-strong correlated (<italic>r</italic>=0.60, <italic>p</italic>&lt;0.001, <italic>n</italic>=36). Subgroup analysis showed that these correlations were only present in the CIS and RRMS patients (<xref ref-type="table" rid="table4-1352458511433306">Table 4</xref>). The results shown in <xref ref-type="table" rid="table4-1352458511433306">Table 4</xref> show that the highest CSF levels of 8,12-iso-iPF2alpha-VI were present in RRMS and SPMS patients. However, the differences with controls and PPMS patients were too small to reach statistical significance. No differences were observed in the plasma levels or the CSF/plasma ratios between the clinical subtypes, nor were there any correlations with EDSS (<italic>n</italic>=29), T1LL, T2LL, black hole volume in the MS patients (<italic>n</italic>=24, data not shown). Seven patients received interferon therapy, but exclusion of these patients from the analysis leads to similar results (data not shown).</p>
<table-wrap id="table4-1352458511433306" position="float">
<label>Table 4.</label>
<caption>
<p>Patient characteristics and isoprostane levels in the CSF-plasma cohort.</p>
</caption>
<graphic alternate-form-of="table4-1352458511433306" xlink:href="10.1177_1352458511433306-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Control</th>
<th align="left">RRMS</th>
<th align="left">SPMS</th>
<th align="left">PPMS</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>n</italic></td>
<td>8</td>
<td>10</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>Female /male ratio</td>
<td>2/6</td>
<td>5/5</td>
<td>3/6</td>
<td>4/6</td>
</tr>
<tr>
<td>Age (years)</td>
<td>49.0 (15.0)</td>
<td>43.6 (7.9)</td>
<td>49.6 (6.7)</td>
<td>53.0 (5.0)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td/>
<td>8.0 (6.2)</td>
<td>16.8 (6.8)<sup><xref ref-type="table-fn" rid="table-fn13-1352458511433306">a</xref></sup></td>
<td>12.1 (7.8)</td>
</tr>
<tr>
<td>EDSS</td>
<td/>
<td>3.3 (1.1)</td>
<td>6.1 (1.5)<sup><xref ref-type="table-fn" rid="table-fn14-1352458511433306">b</xref></sup></td>
<td>4.4 (1.4)</td>
</tr>
<tr>
<td>Correlation coefficient CSF-plasma</td>
<td>0.571 (ns)</td>
<td>0.783 (p=0.013)</td>
<td>0.686 (p=0.041)</td>
<td>0.491 (ns)</td>
</tr>
<tr>
<td>T2LL</td>
<td/>
<td>2704 (1338–5207)</td>
<td>4710 (2837–9204)</td>
<td>3725 (481–7932)</td>
</tr>
<tr>
<td>T1LL (black hole volume)</td>
<td/>
<td>158.5 (74–424)</td>
<td>1045 (231–1986)</td>
<td>33.5 (0–2388)</td>
</tr>
<tr>
<td>GADLL</td>
<td/>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
</tr>
<tr>
<td>Normalised brain volume</td>
<td/>
<td>1238 (1112–1273)</td>
<td>1163 (1034–1276)</td>
<td>1281 (1194–1372)</td>
</tr>
<tr>
<td>Isoprostanes CSF (pg/ml)</td>
<td>64.5 (32–88.8)</td>
<td>82.5 (49–100.8)</td>
<td>81 (57–97)</td>
<td>64.5 (45.4–85.3)</td>
</tr>
<tr>
<td>Isoprostanes plasma (pg/ml)</td>
<td>180 (125.4–243.4)</td>
<td>204.5 (159.3–280.3)</td>
<td>196.2 (111.8–291.8)</td>
<td>212.9 (126.3–258.9)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-1352458511433306">
<p>EDSS: Expanded Disability Status Scale; GADLL: gadolinium enhancing lesions; MS: multiple sclerosis; PPMS: primary progressive MS; RRMS: relapsing–remitting MS; ns: not significant; SPMS: secondary progressive MS; T1LL: T1 hypointense lesion load; T2LL: T2 lesion load volume.</p>
</fn>
<fn id="table-fn12-1352458511433306">
<p>Age, disease duration and EDSS are represented by means (SD). All other variables as medians (IQR). Data are presented as means and standard deviation or median and interquartile range.</p>
</fn>
<fn id="table-fn13-1352458511433306">
<label>a</label>
<p>Significantly different from RRMS patients (analysis of variance (ANOVA), <italic>p</italic>&lt;0.05, Scheffe’s post-hoc test).</p>
</fn>
<fn id="table-fn14-1352458511433306">
<label>b</label>
<p>Significantly different from RR and PP MS patients (ANOVA, <italic>p</italic>&lt;0.001, Scheffe’s post-hoc test).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
</sec>
<sec id="section21-1352458511433306" sec-type="discussion">
<title>Discussion</title>
<p>The results of this study show that levels of this isoprostane were comparable between CIS and RRMS patients. Elevlevated plasma 8,12-iso-iPF2alpha-VI levels in CIS and RRMS patients compared to PPMS patients. No relation was discerned between baseline plasma isoprostane levels and clinical disease or MRI parameters at follow-up. So far, this is the first study comparing plasma isoprostane levels between CIS and definite MS patients and studying the relation with disease progression at follow-up. Several studies on biomarkers for conversion from CIS into MS have been published so far; however, no biomarker in plasma has yet been identified to reliably predict conversion.<sup><xref ref-type="bibr" rid="bibr26-1352458511433306">26</xref><xref ref-type="bibr" rid="bibr27-1352458511433306"/><xref ref-type="bibr" rid="bibr28-1352458511433306"/><xref ref-type="bibr" rid="bibr29-1352458511433306"/><xref ref-type="bibr" rid="bibr30-1352458511433306"/><xref ref-type="bibr" rid="bibr31-1352458511433306"/>–<xref ref-type="bibr" rid="bibr32-1352458511433306">32</xref></sup> Prediction of conversion into MS and early diagnosis of MS would allow a timely start of treatment which enhances the possibility of effectiveness.<sup><xref ref-type="bibr" rid="bibr33-1352458511433306">33</xref></sup> In addition, it would improve the opportunities to provide the patient with more information about future progression.</p>
<p>We questioned whether relatively high F2-isoprostane levels in CIS patients were predictive for disease conversion or rate of progression. There was no relation of the 8,12-iso-iPF2alpha-VI levels with several clinical and MRI disease parameters for disease progression over two years time and this suggests that this isoprostane is not a strong prognostic biomarker.</p>
<p>CSF 8,12-iso-iPF2alpha-VI isoprostane levels tended to be higher in RRMS and SPMS patients compared to neurological controls and PPMS patients, though a large overlap was present and no statistical significance was reached. Our CSF results are in agreement with one study on the same isoprostane, which also did not observe such an increase in the CSF of MS patients compared to inflammatory and non-inflammatory neurological control patients for 8,12-iso-iPF2alpha-VI.<sup><xref ref-type="bibr" rid="bibr14-1352458511433306">14</xref></sup> CSF levels of another isoprostane, 8-epi-prostaglandin (PG)-F2alpha, were shown to be three times higher in 26 RRMS patients compared to eight neurological control patients in another previous study where isoprostane-mixtures were measured using a commercial enzyme immunoassay.<sup><xref ref-type="bibr" rid="bibr11-1352458511433306">11</xref></sup> The intermediate-strong correlation between CSF and plasma observed in the current study indicate that plasma isoprostane levels may be as equally informative as CSF in MS patients.</p>
<p>The plasma levels in RRMS and PPMS patients of the CSF cohort were far higher than in the longitudinal plasma cohort. Similar large differences in levels between studies using the same assay have been reported before for this marker and could be due to variability in the assay and in pre-analytical factors.<sup><xref ref-type="bibr" rid="bibr34-1352458511433306">34</xref>,<xref ref-type="bibr" rid="bibr35-1352458511433306">35</xref></sup> Isoprostanes are sensitive to autooxidation and the addition of butylated hydroxytoluene (BHT) to the plasma samples before freezing in the longitudinal cohort could have caused the relatively low isoprostane levels in this cohort. Another remarkable feature was that no significant differences between RRMS and PPMS patients were present in the CSF/plasma cohort in contrast to the findings in the longitudinal plasma cohort. This could be due to the smaller group size of the RRMS patients in the CSF/plasma cohort, although the number of PPMS patients in the CSF cohort was twice as high. Another explanation could be the differences in cohorts: up to three times higher age, disease duration and EDSS scores of the RRMS patients in the CSF/plasma cohort. It could be possible that the differences between RRMS and PPMS patients are more pronounced in the early stages of the relapse-onset disease process. Expansion of the numbers of patients, inclusion of patients in a large range of disease durations and EDSS scores and controlling collection procedures (e.g. adding BHT to avoid autooxidation) are needed to clarify this issue. If confirmed, higher plasma levels of 8,12-iso-iPF2alpha-VI in CIS and RRMS patients compared to the PP patients in the plasma cohort might reflect a relatively higher level of oxidative stress in relapse-onset MS patients.<sup><xref ref-type="bibr" rid="bibr19-1352458511433306">19</xref></sup></p>
<p>Half of the patients had a relapse but few had GADLL indicative of ongoing inflammation. Active lesion formation may be accompanied by more oxidative stress. However, we expect that biomarker elevations during such events of relatively short duration will merely reflect the acute phenomenon, which will cover effects on predictive values for long-term follow-up. Moreover, 39–43% of the relapse-onset patients had a relapse, and this had no effect on plasma isoprostane level, so acute disease activity likely has minimally confounded the relation between 8,12-iso-iPF2alpha-VI levels and disease progression.</p>
<p>The comparable levels found in CIS and RRMS patients are in contrast to our expectations, as the idea is that CIS and RR share a common pathology involving oxidative stress, but that the intensity is higher in RRMS.<sup><xref ref-type="bibr" rid="bibr18-1352458511433306">18</xref></sup> Thus, the level of oxidative stress as measured by 8,12-iso-iPF2alpha-VI isoprostane levels in body fluids is likely constant during these early phases of MS.</p>
<p>In conclusion, our results do not support a strong role of 8,12-iso-iPF2alpha-VI in the prediction of disease progression in MS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>CE Teunissen was supported by the Dutch MS Research Foundation [Grant 02-358b MS].</p>
</fn>
<fn fn-type="conflict">
<label>Conflicts of interest</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511433306">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bitsch</surname><given-names>A</given-names></name>
<name><surname>Schuchardt</surname><given-names>J</given-names></name>
<name><surname>Bunkowski</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation</article-title>. <source>Brain</source> <year>2000</year>; <volume>123</volume>: <fpage>1174</fpage>–<lpage>1183</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511433306">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bö</surname><given-names>L</given-names></name>
<name><surname>Dawson</surname><given-names>TM</given-names></name>
<name><surname>Wesselingh</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains</article-title>. <source>Ann Neurol</source> <year>1994</year>; <volume>36</volume>: <fpage>778</fpage>–<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511433306">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Horssen</surname><given-names>J</given-names></name>
<name><surname>Schreibelt</surname><given-names>G</given-names></name>
<name><surname>Bo</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>NAD(P)H: quinone oxidoreductase 1 expression in multiple sclerosis lesions</article-title>. <source>Free Radic Biol Med</source> <year>2006</year>; <volume>41</volume>: <fpage>311</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511433306">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>KJ</given-names></name>
<name><surname>Kapoor</surname><given-names>R</given-names></name>
<name><surname>Hall</surname><given-names>SM</given-names></name>
<etal/>
</person-group>. <article-title>Electrically active axons degenerate when exposed to nitric oxide</article-title>. <source>Ann Neurol</source> <year>2001</year>; <volume>49</volume>: <fpage>470</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511433306">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qi</surname><given-names>X</given-names></name>
<name><surname>Lewin</surname><given-names>AS</given-names></name>
<name><surname>Sun</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis</article-title>. <source>J Biol Chem</source> <year>2006</year>; <volume>281</volume>: <fpage>31950</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511433306">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Besler</surname><given-names>HT</given-names></name>
<name><surname>Comoglu</surname><given-names>S</given-names></name>
<name><surname>Okcu</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis</article-title>. <source>Nutr Neurosci</source> <year>2002</year>; <volume>5</volume>: <fpage>215</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511433306">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Besler</surname><given-names>HT</given-names></name>
<name><surname>Comoglu</surname><given-names>S</given-names></name>
</person-group>. <article-title>Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis</article-title>. <source>Nutr Neurosci</source> <year>2003</year>; <volume>6</volume>: <fpage>189</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511433306">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ristori</surname><given-names>G</given-names></name>
<name><surname>Brescianini</surname><given-names>S</given-names></name>
<name><surname>Pino</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Serum elements and oxidative status in clinically isolated syndromes: imbalance and predictivity</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>549</fpage>–<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511433306">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferretti</surname><given-names>G</given-names></name>
<name><surname>Bacchetti</surname><given-names>T</given-names></name>
<name><surname>Principi</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity</article-title>. <source>Mult Scler</source> <year>2005</year>; <volume>11</volume>: <fpage>677</fpage>–<lpage>682</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511433306">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koch</surname><given-names>M</given-names></name>
<name><surname>Mostert</surname><given-names>J</given-names></name>
<name><surname>Arutjunyan</surname><given-names>AV</given-names></name>
<etal/>
</person-group>. <article-title>Plasma lipid peroxidation and progression of disability in multiple sclerosis</article-title>. <source>Eur J Neurol</source> <year>2007</year>; <volume>14</volume>: <fpage>529</fpage>–<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511433306">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greco</surname><given-names>A</given-names></name>
<name><surname>Minghetti</surname><given-names>L</given-names></name>
<name><surname>Sette</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis</article-title>. <source>Neurology</source> <year>1999</year>; <volume>53</volume>: <fpage>1876</fpage>–<lpage>1879</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511433306">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greco</surname><given-names>A</given-names></name>
<name><surname>Minghetti</surname><given-names>L</given-names></name>
<name><surname>Puopolo</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2004</year>; <volume>224</volume>: <fpage>23</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511433306">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>E</given-names></name>
<name><surname>Mrowicka</surname><given-names>M</given-names></name>
<name><surname>Saluk-Juszczak</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis</article-title>. <source>Neurochem Res</source> <year>2011</year>; <volume>36</volume>: <fpage>1012</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr14-1352458511433306">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mattsson</surname><given-names>N</given-names></name>
<name><surname>Haghighi</surname><given-names>S</given-names></name>
<name><surname>Andersen</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients</article-title>. <source>Neurosci Lett</source> <year>2007</year>; <volume>414</volume>: <fpage>233</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511433306">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Leon</surname><given-names>MJ</given-names></name>
<name><surname>DeSanti</surname><given-names>S</given-names></name>
<name><surname>Zinkowski</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment</article-title>. <source>Neurobiol Aging</source> <year>2006</year>; <volume>27</volume>: <fpage>394</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511433306">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pratico</surname><given-names>D</given-names></name>
<name><surname>Clark</surname><given-names>CM</given-names></name>
<name><surname>Liun</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease</article-title>. <source>Arch Neurol</source> <year>2002</year>; <volume>59</volume>: <fpage>972</fpage>–<lpage>976</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511433306">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kester</surname><given-names>MI</given-names></name>
<name><surname>Scheffer</surname><given-names>PG</given-names></name>
<name><surname>Koel-Simmelink</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. <article-title>Serial CSF sampling in Alzheimer’s disease: specific versus non-specific markers</article-title>. <source>Neurobiol Aging</source> <year>2011</year>.</citation>
</ref>
<ref id="bibr18-1352458511433306">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>D</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Montalban</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management</article-title>. <source>Lancet Neurol</source> <year>2005</year>; <volume>4</volume>: <fpage>341</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511433306">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bruck</surname><given-names>W</given-names></name>
<name><surname>Lucchinetti</surname><given-names>C</given-names></name>
<name><surname>Lassmann</surname><given-names>H</given-names></name>
</person-group>. <article-title>The pathology of primary progressive multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2002</year>; <volume>8</volume>: <fpage>93</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr20-1352458511433306">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poser</surname><given-names>CM</given-names></name>
<name><surname>Paty</surname><given-names>DW</given-names></name>
<name><surname>Scheinberg</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</article-title>. <source>Ann Neurol</source> <year>1983</year>; <volume>13</volume>: <fpage>227</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511433306">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Filippi</surname><given-names>M</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis</article-title>. <source>Brain</source> <year>1997</year>; <volume>120</volume>: <fpage>2059</fpage>–<lpage>2069</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511433306">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cutter</surname><given-names>GR</given-names></name>
<name><surname>Baier</surname><given-names>ML</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. <article-title>Development of a multiple sclerosis functional composite as a clinical trial outcome measure</article-title>. <source>Brain</source> <year>1999</year>; <volume>122</volume>: <fpage>871</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr23-1352458511433306">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title>. <source>Neurology</source> <year>1983</year>; <volume>33</volume>: <fpage>1444</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr24-1352458511433306">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teunissen</surname><given-names>CE</given-names></name>
<name><surname>Petzold</surname><given-names>A</given-names></name>
<name><surname>Bennett</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking</article-title>. <source>Neurology</source> <year>2009</year>; <volume>73</volume>: <fpage>1914</fpage>–<lpage>1922</lpage>.</citation>
</ref>
<ref id="bibr25-1352458511433306">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lublin</surname><given-names>FD</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
</person-group>. <article-title>Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis</article-title>. <source>Neurology</source> <year>1996</year>; <volume>46</volume>: <fpage>907</fpage>–<lpage>911</lpage>.</citation>
</ref>
<ref id="bibr26-1352458511433306">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qin</surname><given-names>Y</given-names></name>
<name><surname>Duquette</surname><given-names>P</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis</article-title>. <source>Lab Invest</source> <year>2003</year>; <volume>83</volume>: <fpage>1081</fpage>–<lpage>1088</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511433306">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berger</surname><given-names>T</given-names></name>
<name><surname>Rubner</surname><given-names>P</given-names></name>
<name><surname>Schautzer</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event</article-title>. <source>N Engl J Med</source> <year>2003</year>; <volume>349</volume>: <fpage>139</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511433306">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>ET</given-names></name>
<name><surname>Berger</surname><given-names>T</given-names></name>
<name><surname>Reindl</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2005</year>; <volume>11</volume>: <fpage>492</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511433306">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tumani</surname><given-names>H</given-names></name>
<name><surname>Lehmensiek</surname><given-names>V</given-names></name>
<name><surname>Rau</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis</article-title>. <source>Neurosci Lett</source> <year>2009</year>; <volume>452</volume>: <fpage>214</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511433306">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Comabella</surname><given-names>M</given-names></name>
<name><surname>Montalban</surname><given-names>X</given-names></name>
<name><surname>Kakalacheva</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS</article-title>. <source>J Neuroimmunol</source> <year>2010</year>; <volume>223</volume>: <fpage>135</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr31-1352458511433306">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brettschneider</surname><given-names>J</given-names></name>
<name><surname>Czerwoniak</surname><given-names>A</given-names></name>
<name><surname>Senel</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)</article-title>. <source>PLoS One</source> <year>2010</year>; <volume>5</volume>: <fpage>e11986</fpage>.</citation>
</ref>
<ref id="bibr32-1352458511433306">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ristori</surname><given-names>G</given-names></name>
<name><surname>Brescianini</surname><given-names>S</given-names></name>
<name><surname>Pino</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Serum elements and oxidative status in clinically isolated syndromes: imbalance and predictivity</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>549</fpage>–<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr33-1352458511433306">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>D</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Montalban</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis</article-title>. <source>Lancet Neurol</source> <year>2005</year>; <volume>4</volume>: <fpage>281</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr34-1352458511433306">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mufson</surname><given-names>EJ</given-names></name>
<name><surname>Leurgans</surname><given-names>S</given-names></name>
</person-group>. <article-title>Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer’s disease</article-title>. <source>Neurodegener Dis</source> <year>2010</year>; <volume>7</volume>: <fpage>139</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr35-1352458511433306">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irizarry</surname><given-names>MC</given-names></name>
<name><surname>Yao</surname><given-names>Y</given-names></name>
<name><surname>Hyman</surname><given-names>BT</given-names></name>
<etal/>
</person-group>. <article-title>Plasma F2A isoprostane levels in Alzheimer’s and Parkinson’s disease</article-title>. <source>Neurodegener Dis</source> <year>2007</year>; <volume>4</volume>: <fpage>403</fpage>–<lpage>405</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>